Aju IB Investment Co., Ltd. Overview
Aju IB Investment is Korea's oldest venture capital firm, originating in 1974 as a KIST-funded technology-commercialisation vehicle. It is now the alternative-investment arm of the mid-sized Aju Group. The firm manages roughly KRW 2.5 trn of third-party capital across venture funds and private equity vehicles. It invests across the full lifecycle, from accelerator-stage seed deals through growth venture rounds to control buyouts such as the 2026 acquisition of airport-lounge platform E-Bridge. Its distinguishing asset is a decade-old US platform: Solasta Ventures in Boston (biotech) and Solasta Nexus in Silicon Valley (deep tech). Through these, it reports 19 Nasdaq portfolio listings and holds an undisclosed stake in SpaceX. Earnings combine a steady management-fee base with highly cyclical performance fees and mark-to-market gains. This produced a record 1H 2026, followed by an 85% share-price collapse from its April 2026 peak.
What the company does
Aju IB Investment is a fund manager and principal investor. It raises capital from limited partners (LPs), including the National Pension Service, the Korea Development Bank's growth funds, Korea Venture Investment Corp. (Fund of Funds), mutual-aid associations and corporates. It deploys that capital into unlisted Korean and US companies through venture funds (투자조합) and private equity funds (사모투자합자회사). As general partner, the company commits its own balance-sheet capital (the "GP commitment") alongside LPs. It also invests directly from its proprietary account. It earns returns through four channels:
-
Management fees (관리보수): recurring fees on committed or invested capital. 1H 2024 management fees were KRW 9.13 bn (Asiae CORE, 14 Aug 2024).
-
Performance fees (성과보수, carried interest): paid when a fund is liquidated with an IRR above its hurdle. These were KRW 10.2 bn in FY2023 and KRW 4.5 bn in FY2024 (Dealsite, 16 May 2025).
-
Equity-method income (지분법이익): the company's share of profits in funds it does not consolidate, generally where its stake is below 20% (Dealsite, 15 May 2019).
-
Investment-asset gains (투자자산관련수익): fair-value and disposal gains on proprietary and consolidated-fund holdings, recognised as FVTPL (fair value through profit or loss).
By 1Q 2026 revenue composition, Butler reports equity-method income at 35%, management fees at 24%, performance fees at 21%, investment-asset income at 15% and other operating revenue at 5%.
Revenue model characterisation
The revenue model is almost entirely service-and-carry plus principal investment returns. There is no product, subscription or licensing revenue. Management fees act as an annuity-like floor. Performance fees and fair-value gains create large swings tied to IPO windows on KOSDAQ and Nasdaq. The company said in early 2025 that most of its exits are realised through KOSDAQ, so a KOSDAQ decline of more than 20% in 2024 fed directly into weaker results (Dealsite, 14 Feb 2025).
Value-chain position, customers and end-markets
Aju IB sits between institutional capital providers (its "customers" as LPs) and investee companies. Its end-markets are the sectors it invests in:
Biotech and healthcare: both in Korea and through Solasta Ventures in Boston.
Deep tech and ICT: AI, robotics, cloud, autonomous mobility, space and semiconductors, via Solasta Nexus and Korean funds.
Materials, parts and equipment (소부장): for example Nextil and Nanoteam.
Consumer and platform businesses: for example Yanolja, Delicious and E-Bridge.
Mid-market buyouts: through the Aju Good PEF series.
Company self-description vs independent characterisation
In public statements, the company describes itself as an alternative-investment specialist. It emphasises its full-cycle pipeline from accelerator through VC to PE, and its first-generation track record (Asiae CORE, 27 Aug 2026). CEO Kim Ji-won has repeatedly framed the strategy as balancing domestic and overseas investing, and VC with PE, to build a stable earnings structure (Dealsite, 2 Feb 2021).
Independent characterisation: Aju IB is a mid-to-large Korean VC/PE house. Its listed equity is effectively a levered call option on (a) KOSDAQ IPO conditions, (b) a handful of large US positions (historically Arcellx, Kymera and Atea; currently SpaceX and a set of AI infrastructure names), and (c) fundraising success under Korea's expanding policy-capital programmes such as the National Growth Fund. The fee base, roughly KRW 18–20 bn per year, covers operating costs of about KRW 16 bn in SG&A. Profitability above breakeven therefore depends on realisations and marks.
Strategy
Stated strategic themes
Recurring themes in management statements are:
-
Full-cycle investing: from accelerator through VC to PE (Asiae CORE, 27 Aug 2026).
-
Global platform: Boston for biotech, Silicon Valley for deep tech, and Japan through LP positions.
-
AUM scale-up: to expand the management-fee floor and reduce reliance on markets. The CEO said in May 2025 that the firm would not rely solely on market conditions (Asiae English, 16 May 2025).
-
Balanced earnings mix: across domestic and overseas, VC and PE (Dealsite, 2 Feb 2021).
-
Shareholder value: steady dividends and AUM-driven earnings growth.
Initiatives in the last 24 months
| Initiative | Timing | Detail | Source |
|---|---|---|---|
| Solasta Nexus incorporation | Announced Feb 2025; completed Jun 2026 | Silicon Valley branch converted to an entity; dedicated frontier-tech fund | Dealsite, 14 Feb 2025; Asiae CORE, 27 Aug 2026 |
| Solasta Nexus Frontier-Tech Fund | 2025–26 | KRW 50 bn target; AI, digital transformation, robotics, space and climate | Asiae CORE, 18 Jun 2025 |
| Aju Good Venture Fund 3.0 | 2,025 | KRW 200 bn+ target; KRW 182 bn LOCs secured | Dealsite, 16 May 2025 |
| Aju Good No.4 PEF | Dec 2025 – Mar 2026 | Closed at KRW 316 bn | Asiae, 14 Aug 2026 |
| E-Bridge buyout | SPA Dec 2025; closing Apr 2026 | ~KRW 250 bn; first control deal from No.4; plans for overseas network and tie-ups with conglomerate retail and tourism affiliates; exit options include IPO | Dealsite, 11 Feb 2026 |
| Accelerator Division | Jan 2026 | First large Korean VC to run AC as a full division | Asiae CORE, 27 Aug 2026 |
| National Growth Fund GP | 1H 2026 | KRW 43 bn commitment (small-league indirect investment, Shinhan AM-managed); Super-Gap Scale-up 2.0 target KRW 200 bn | Asiae CORE, 27 Aug 2026 |
| Teachers' Pension (사학연금) shortlist | Jul 2026 | Potential matching capital for the 2.0 fund | Dealsite, 22 Jul 2026 |
| Japan LP programme | 2,025 | First commitments to Japanese VC funds | Asiae CORE, 27 Aug 2026 |
| Accelerated deployment | 1H 2026 | ~KRW 150 bn invested; dry powder fell from KRW 283.4 bn to KRW 134.5 bn, positioning for new fund closes | Dealsite, 22 Jul 2026 |
ESG and cost programmes
No sustainability-linked commitments or formal cost-reduction programmes with targets were identified.
Medium-term targets and guidance
No numeric earnings guidance was identified. Qualitative and operational targets include:
-
About KRW 500 bn of new fund capacity from Venture Fund 3.0, No.4 PEF and Frontier-Tech (May 2025 plan; Dealsite, 16 May 2025).
-
More than ten portfolio IPOs in 2H 2026 (Asiae, 14 Aug 2026).
-
Average fundraising of about KRW 150 bn per year (six funds totalling KRW 741.8 bn over five years), to be lifted by the 2.0 fund (Asiae CORE, 27 Aug 2026).
Products & Services
Aju IB's "products" are its funds and investment programmes. The catalogue below lists every fund vehicle identified in public sources. Committed size is shown in KRW where disclosed. Management-fee rates and carry terms are not publicly disclosed for individual funds.
Venture capital funds (domestic)
| Fund | Year | Size | Target / notes | Status |
|---|---|---|---|---|
| Aju Good Venture Fund (아주 좋은 벤처펀드) | 2,017 | KRW 100 bn | Generalist venture | — |
| Aju Good Venture Fund 2.0 | — | — | Generated KRW 1.5 bn of fees in 1H 2023 | Active (Dealsite, 16 Aug 2024) |
| Aju Good Venture Fund 3.0 | 2,025 | Target KRW 200 bn+; KRW 182 bn LOCs by May 2025 from NPS, POBA and Science & Technology mutual-aid association | Flagship VC fund | — |
| Aju Good Growth Support Fund (아주좋은성장지원펀드) | 2,018 | KRW 175 bn | Growth stage | Active (Dealsite, 15 May 2019) |
| NH-Aju KOSDAQ Scale-up Fund | 2,019 | KRW 106 bn | KOSDAQ scale-up co-GP with NH | — |
| Aju Good Super-Gap Scale-up Fund (초격차 스케일업펀드) | Dec 2023 / 2024 | KRW 60 bn first close, KRW 100 bn total | Deep-tech "super-gap" sectors | Investing (Dealsite, 15 Feb 2024 & 16 May 2025) |
| Aju Good Super-Gap Scale-up 2.0 Fund | 2026 (forming) | Target KRW 200 bn hard cap; KRW 43 bn National Growth Fund commitment; possible Teachers' Pension matching | Lead manager: Park Se-geun | Fundraising (Asiae CORE, 27 Aug 2026; Dealsite, 22 Jul 2026) |
| Policy-type New Deal Fund | 2,021 | Target KRW 150 bn | Digital/green New Deal; NPS matching | — |
| Aju Good Growth 2 Fund (아주좋은그로쓰2호) | — | — | Holds Nanoteam | Harvesting (Dealsite, 16 May 2025) |
| Aju Good Technology Finance Fund (기술금융 펀드) | — | — | Equity-method income of KRW 4.0 bn in 1Q 2023 | Active (Dealsite, 28 May 2024) |
| Aju Growth & Healthcare Fund | ~2017 | — | Invested in Gridwiz Series B | Active (Dealsite, 14 Aug 2024) |
| Aju Early Commercialisation Fund (아주초기사업화투자조합) | 2,016 | KRW 25 bn | Early stage; Gridwiz Series A | Liquidated 2024 (Dealsite, 16 May 2025) |
| 2014 KIF-Aju IT Fund | 2,014 | KRW 31 bn | ICT | Liquidated 1H 2024 |
| Aju Digital Contents Fund | — | KRW 26 bn | Content | Liquidated 1Q 2025 (Dealsite, 16 May 2025) |
| IBKC-Aju IB IDiscovery Fund 1 | — | KRW 7.2 bn | Co-GP with IBK Capital | Liquidated 1Q 2025 |
| Aju December Nox Fund | 2,023 | KRW 24.8 bn | Project fund | Active (Dealsite, 15 Feb 2024) |
Overseas-dedicated funds
| Fund | Year | Size | Focus | Status |
|---|---|---|---|---|
| Aju Life Science Overseas Expansion Platform Fund | — | Part of KRW 215 bn combined | US biotech | Active as of Jan 2021 |
| Aju Growth & Healthcare | — | Part of KRW 215 bn combined | Cross-border healthcare | Active as of Jan 2021 |
| Aju Good Life Science 3.0 | Jul 2018 | KRW 123 bn | US biotech via Solasta | Active (Dealsite, 2 Jul 2019) |
| Aju Life Science 4.0 | 2,021 | Planned KRW 100 bn+; Aju Industrial committed KRW 10 bn | US biotech | — |
| Solasta Nexus Frontier-Tech Fund | 2025–26 (forming) | Target KRW 50 bn | AI, digital transformation, robotics, space and climate tech | Fundraising (Asiae CORE, 18 Jun 2025; Dealsite, 16 May 2025) |
Private equity funds
| Fund | Year | Size | Notable holdings / notes | Status |
|---|---|---|---|---|
| Aju Good PEF (아주좋은 사모투자합자회사) | 2,017 | KRW 250 bn | Yanolja; Point Mobile (28.3% with overseas fund, 2020) | Harvesting; top fee contributor in FY2023 at KRW 7.4 bn (Dealsite, 16 May 2025) |
| Aju Good PEF No.2 | ~2019–20 | KRW 136 bn first close, expanding | Point Mobile sourcing | 7 Jan 2021) |
| Aju Good PEF No.3 | 2,023 | KRW 267.9 bn | Mid-market | Investing (Dealsite, 15 Feb 2024) |
| Aju Good No.4 PEF | Dec 2025 / Mar 2026 | KRW 316 bn after second close; anchored by KDB Innovation Growth Fund (KRW 100 bn) and Korea Eximbank | First deal: E-Bridge | Investing (Asiae, 14 Aug 2026; Dealsite, 11 Feb 2026) |
| Aju E-Bridge Fund | 2,026 | KRW 146.4 bn | Project fund co-investing in E-Bridge | Invested |
| NH-Aju IB SME/Mid-cap Growth 2013 PEF | 2,013 | KRW 200 bn | Mid-cap growth | Liquidated 2024 |
| Wonik-Aju Turnaround No.1 PEF | — | KRW 47 bn | Turnaround; Nextil Holdings | Liquidated 2024 |
Proprietary and direct investment
The company also invests from its own account. For example, it held 6.05% of HNS Hitech directly on balance sheet in 2024 (Dealsite, 14 Aug 2024). FVTPL financial assets on the consolidated balance sheet were KRW 129.7 bn at 30 June 2026, up from KRW 89.4 bn at end-2025 (Valueline).
Flagship portfolio companies (named in public sources)
| Company | Country | Sector | Status / outcome |
|---|---|---|---|
| SpaceX | US | Space / satellite (merged with xAI Feb 2026) | Invested 1H 2023 via Solasta SPV; listed on Nasdaq 12 Jun 2026; stake undisclosed |
| Arcellx | US | CAR-T cell therapy | KRW 17.4 bn invested; KRW 167.5 bn recovered (~10x); Gilead acquisition agreed Feb 2026 for USD 7.8 bn |
| Kymera Therapeutics | US | Targeted protein degradation | KRW 5.7 bn → KRW 64.1 bn |
| Atea Pharmaceuticals | US | Antivirals | KRW 9.2 bn → KRW 92.5 bn |
| Seer | US | Proteomics | Nasdaq IPO Dec 2020 |
| Apellis Pharmaceuticals | US | Complement therapeutics | Listed; realisation details not disclosed |
| Rescale, Cohere, Lambda, Databricks | US | Cloud HPC, generative AI, AI cloud, data analytics | Held via Silicon Valley platform (Herald, 28 Apr 2026) |
| Ridecell, Tibit Communications | US | Autonomous mobility platform, telecom equipment | Silicon Valley portfolio (Dealsite, 26 Jan 2021) |
| Yanolja | Korea | Travel platform | Invested 2017; IPO delayed; SoftBank valued it at KRW 8 trn in 2021 |
| Krafton | Korea | Games | Investment cited as a share-price catalyst in 2020–21 |
| Pearl Abyss | Korea | Games | KRW 2 bn → KRW 11 bn |
| Nextil | Korea | Seamless steel pipe | ~4x / IRR 45% |
| Nanoteam | Korea | Materials/parts | IPO Mar 2023 at KRW 13,000; trading ~KRW 5,270 (Aug 2026) |
| Udang Technology | Korea | Industrial | Sold to TKG Aekang; IRR 26%; KRW 55 bn sale, KRW 71.5 bn total recovery |
| Gridwiz, Laser Optek, HNS Hitech, Organoid Sciences, Inventage Lab, Next Biomedical, Onconic Therapeutics, Dotmill | Korea | Energy, devices, biotech | IPOs/listings 2024–25 |
| Canaf Therapeutics, IM Biologics, Mezoo, Lemon Healthcare, Delicious | Korea | Biotech, digital health, fashion B2B | IPOs Jan–Aug 2026 |
| Dabeeo, PGT, MBD, NexI | Korea | Spatial AI, specialty chemicals, organoid medicine, immuno-oncology | IPO pipeline 2H 2026 |
| E-Bridge | Korea | Airport lounge platform ("The Lounge") | 100% buyout, ~KRW 250 bn |
| DeepX, Hutom, Sizzle, Bonzak, Pebble-i, Kovis Technology, SigGenGuru, Hurotics, Homecheck | Korea | AI chips, surgical AI, others | Part of ~200 companies invested since 2015 (Dealsite, 6 Feb 2025) |
Financial Narrative
Income statement
Revenue is operating revenue (영업수익). Gross profit and EBITDA are not reported by Korean financial-company formats and are not meaningful for a VC.
Sources: FY2021–FY2025 revenue, OI and NI from Butler (company page 00156895). FY2023 and FY2024 confirmed against Dealsite (15 Feb 2024; 16 May 2025; 27 Mar 2025). FY2025 pre-tax income from Valueline. EPS is derived as NI divided by year-end shares (120.82 m, 120.82 m, 120.85 m, 120.95 m, 121.15 m), not reported diluted EPS. FY2025 DPS from ETFShopping.
Extended history (for context):
Sources: FY2019 and FY2020 from Dealsite (12 Feb 2020; 2 Feb 2021). FY2018 is derived from reported FY2019 growth rates (revenue −12%, OI +45%, NI +38.5%).
Revenue CAGR. FY2021–FY2024 revenue CAGR was −22.2% (derived). The FY2021 base was inflated by the 2020–21 IPO boom. On an FY2019–FY2024 basis, revenue grew at about +0.5% per year (derived: 64.1 → 65.6), which illustrates the cyclicality.
FY2025 and trailing income detail
Source: Valueline consolidated income statement (TTM columns at 2025/12 and 2026/06).
Quarterly operating income (derived)
Sources and method: Q1 2024 (KRW 6.3 bn), 1H 2024 (KRW 10.8 bn), 9M 2024 (KRW 10.8 bn), Q1 2025 (KRW 0.77 bn), Q1 2026 (KRW 8.1 bn) and Q2 2026 (KRW 38.1 bn) are reported (Dealsite, Asiae). The remaining quarters are derived from FY totals and Valueline TTM columns (TTM OI: 2025/03 KRW 2.87 bn; 2025/06 KRW 1.44 bn; 2025/09 KRW 3.78 bn; 2025/12 KRW 11.88 bn; 2026/06 KRW 54.21 bn). The derived quarters reconcile to the reported annual figures.
Commentary on income trends
FY2021 (peak cycle): OI of KRW 52.0 bn and NI of KRW 39.3 bn followed the record FY2020 (OI KRW 63.1 bn). Both years benefited from a domestic IPO boom (nine portfolio IPOs in 2020) and Nasdaq biotech listings. Management said more than 30% of 2020 investment gains came from overseas (Dealsite, 2 Feb 2021).
FY2022 (trough): OI collapsed 91% to KRW 4.8 bn and NI to KRW 2.0 bn as listed valuations fell and fair-value marks turned negative.
FY2023 (recovery): Exits at Nextil (~4x), Nanoteam (KRW 22.3 bn partial sale) and Corelinesoft, plus rising management fees from new PEF No.3, lifted OI to KRW 17.7 bn (+266%) and NI to KRW 16.6 bn (+714%) (Dealsite, 15 Feb 2024).
FY2024 (relapse): Performance fees fell 56% to KRW 4.5 bn. SG&A rose KRW 1.3 bn to KRW 16.9 bn, and total operating expenses reached KRW 57.2 bn. KOSDAQ fell more than 20%, producing a 4Q operating loss. OI halved to KRW 8.4 bn (Dealsite, 16 May 2025). Gains on Arcellx and Udang Technology partly offset the decline.
FY2025: A weak 1H (Q1 OI KRW 0.8 bn, hit by tariff-driven market declines) was followed by a stronger 2H. OI reached KRW 11.9 bn and NI was flat at KRW 8.3 bn. Operating cash flow was slightly negative at −KRW 1.1 bn (Valueline TTM).
1H 2026 (inflection): OI of KRW 46.2 bn already exceeded every full year since FY2021. Drivers were higher performance fees, SpaceX fair-value gains and the Arcellx disposals following the Gilead bid (Asiae, 14 Aug 2026). 1H 2026 NI was about KRW 36.2 bn (Valueline balance-sheet line for current-period NI). TTM ROE reached 13.9% (Valueline).
Balance sheet
Source: Valueline consolidated balance sheet. FY2021 balance-sheet detail was not available in the sources reviewed.
Notes:
-
Net debt is derived as total borrowing liabilities less cash and deposits. "Other borrowing liabilities" may include lease liabilities and borrowings at consolidated fund level.
-
The balance sheet is unclassified (financial-company format), so working capital is not meaningful.
-
Treasury shares fell to zero by 30 June 2026 while capital surplus rose from KRW 20.8 bn to KRW 23.3 bn. This indicates the treasury stock was disposed of rather than cancelled.
Balance-sheet commentary. Aju IB has de-levered steadily. Total borrowing liabilities fell from KRW 95.6 bn (FY2022) to KRW 30.3 bn (2Q 2026). Total liabilities to equity fell from 53% to 22% (derived). Equity has compounded slowly, from KRW 243.4 bn to KRW 266.9 bn over FY2022–FY2025, constrained by low earnings and dividends. It then jumped KRW 32.4 bn in 1H 2026 on the record profit.
The asset base is dominated by two pools. Equity-method stakes in its own funds (~KRW 144 bn) are the GP commitments. FVTPL holdings (~KRW 130 bn) include consolidated-fund and proprietary positions. The jump in FVTPL assets and deferred tax liabilities in 1H 2026 is consistent with large unrealised gains, notably SpaceX. These gains remain exposed to market reversal. SpaceX shares fell roughly 50% from their post-IPO peak by late July 2026 (Wikipedia, SpaceX IPO article).
Cash flow
Source: Valueline cash-flow page (TTM columns).
Capex is immaterial for the business: PP&E was KRW 4.3–8.0 bn across the period, mostly right-of-use assets. A KRW 5 bn buyback was executed from November 2019 (Dealsite, 12 Feb 2020). For a VC, operating cash flow is distorted by the classification of investment purchases and disposals and is a poor indicator of earning power.
Ratios
Notes: TTM ROE at June 2026 is 13.86% (Valueline). TTM interest coverage at June 2026 is about 43x (derived: KRW 54.21 bn ÷ KRW 1.25 bn). ROIC, current ratio, net debt/EBITDA and cash conversion cycle are not meaningful or not reported for a financial company of this type.
Ratio commentary. Through FY2025, returns on equity in the low single digits were well below any reasonable cost of equity. This explains why the stock traded near or slightly above book (P/B 1.1–1.3x) despite large mark-to-market assets. The 1H 2026 profit lifted TTM ROE to about 14%. The key question for valuation is whether this is repeatable or a one-off crystallisation of SpaceX and Arcellx value.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Units
| Unit | Content | Key people (as reported) |
|---|---|---|
VC Investment Division | Domestic venture funds (Aju Good Venture Fund series, Super-Gap Scale-up funds, policy funds) | Park Gye-hoon, VC Investment Division head, also AC Division head (Asiae CORE, 27 Aug 2026); Yoon Chang-soo, Venture Investment 1 head per 2021 appointment (Dealsite, 7 Jan 2021) |
Accelerator (AC) Division | Seed and early-stage investing; government-programme consulting; created January 2026 | Park Gye-hoon (concurrent) |
PE Investment Division | Aju Good PEF series (No.3 KRW 267.9 bn; No.4 KRW 316 bn); project funds (Aju E-Bridge Fund KRW 146.4 bn) | Kim Tae-seung appointed PE head in 2021 (Dealsite, 7 Jan 2021); former inside director Choi Yong-jin resigned in early 2025 (Dealsite, 27 Mar 2025). |
Global Investment Division | Cross-border funds; Super-Gap Scale-up 2.0 lead manager | Managing Director Park Se-geun, formerly Samsung SDI, NC and IMM Investment (Dealsite, 22 Jul 2026) |
Risk Management / Compliance | Risk, compliance officer function | Heo Byung-du, CPA (formerly Samil), appointed 2021 (Dealsite, 7 Jan 2021) |
Solasta Ventures (Boston, US) | 100%-owned subsidiary; life-sciences venture investing | Derek (Dong-min) Yoon, head of entity |
Solasta Nexus (Silicon Valley, US) | Deep-tech investing (AI, robotics, space, cloud); branch since 2019, entity since June 2026 | Michael Jeon, partner and head |
Revenue by Segment
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Fee income total (KRW Bn) | 28.0 | 23.1 | 20.4 |
Performance fees (KRW Bn) | 10.2 | 4.5 | — |
Management and other fees, derived (KRW Bn) | 17.8 | 18.6 | — |
Net gains on financial instruments (KRW Bn) | — | — | 5.0 |
Net operating income (KRW Bn) | — | — | 28.0 |
Operating income (KRW Bn) | 17.7 | 8.4 | 11.9 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (FY2024–2Q2026)
| Metric | FY2024 | 2Q2026 |
|---|---|---|
Venture fund AUM (KRW Bn) | 1,387.5 | 1,398.3 |
PE fund AUM (KRW Bn) | 687.9 | 1,150.2 |
Total AUM (KRW Bn) | 2,075.4 | 2,548.5 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating revenue (KRW Bn) | 139.2 | 63.4 | 73.7 | 65.6 | — |
Operating income (KRW Bn) | 52.0 | 4.8 | 17.7 | 8.4 | 11.9 |
Pre-tax income (KRW Bn) | — | — | — | — | 11.7 |
Net income (KRW Bn) | 39.3 | 2.0 | 16.6 | 8.3 | 8.3 |
Basic EPS derived (KRW) | 325 | 17 | 137 | 69 | 69 |
Dividend per share (KRW) | — | — | — | — | 70 |
Operating margin on revenue (%) | 37.4 | 7.6 | 24.0 | 12.8 | — |
Net margin on revenue (%) | 28.2 | 3.2 | 22.5 | 12.7 | — |
Income Statement
| Metric | FY2018 | FY2019 | FY2020 |
|---|---|---|---|
Operating revenue (KRW Bn) | 72.8 | 64.1 | 146.2 |
Operating income (KRW Bn) | 15.0 | 21.7 | 63.1 |
Net income (KRW Bn) | 11.8 | 16.3 | — |
Dividends & Capital Returns
| Line item (KRW Bn) | FY2025 | TTM to Jun-2026 |
|---|---|---|
Interest income | 2.72 | 2.42 |
Interest expense | 1.40 | 1.25 |
Fee income | 20.36 | 34.82 |
Gains on financial instruments | 22.13 | 55.89 |
Losses on financial instruments | 17.13 | 21.67 |
Dividend income | 0.85 | 0.98 |
Net operating income | 27.99 | 70.80 |
SG&A | 16.10 | 16.59 |
Operating income | 11.88 | 54.21 |
Pre-tax income | 11.74 | 54.09 |
Income tax | 3.42 | 12.59 |
Net income | 8.31 | 41.49 |
Key Financials
| Metric | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating income (KRW Bn) | 6.3 | 4.5 | 0.0 | -2.4 | 0.8 | 3.1 | 2.3 | 5.7 | 8.1 | 38.1 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | 2Q2026 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 373.3 | 354.6 | 341.7 | 338.3 | 363.9 |
Cash and deposits (KRW Bn) | 45.0 | 83.7 | 65.9 | 79.8 | 64.5 |
FVTPL financial assets (KRW Bn) | 138.8 | 95.4 | 90.1 | 89.4 | 129.7 |
Equity-method investments (KRW Bn) | 155.1 | 142.9 | 152.3 | 141.7 | 144.0 |
Intangible assets (KRW Bn) | 1.0 | 1.0 | 1.0 | 1.8 | 1.9 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Total liabilities (KRW Bn) | 129.9 | 96.1 | 80.6 | 71.4 | 64.6 |
Total borrowing liabilities (KRW Bn) | 95.6 | 60.2 | 51.2 | 43.9 | 30.3 |
Bank borrowings (KRW Bn) | 28.0 | 24.0 | 24.0 | 24.0 | 16.0 |
Bonds (KRW Bn) | 5.2 | 0 | 0 | 2.6 | 0 |
Other borrowing liabilities (KRW Bn) | 62.3 | 36.2 | 27.2 | 17.3 | 14.3 |
Deferred tax liabilities (KRW Bn) | 13.3 | 11.0 | 8.0 | 8.2 | 15.0 |
Net debt derived (KRW Bn) | 50.6 | -23.5 | -14.7 | -35.9 | -34.2 |
Shareholders' equity (KRW Bn) | 243.4 | 258.5 | 261.1 | 266.9 | 299.3 |
Retained earnings (KRW Bn) | 168.1 | 182.4 | 184.8 | 187.2 | 215.0 |
Treasury shares (KRW Bn) | -3.8 | -3.3 | -3.3 | -1.7 | 0 |
Book value per share derived (KRW) | 2,015 | 2,139 | 2,159 | 2,203 | 2,470 |
Cash Flow
| Metric | FY2025 | TTM to Jun-2026 |
|---|---|---|
Operating cash flow (KRW Bn) | -1.1 | 20.7 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE on average equity derived (%) | — | 6.6 | 3.2 | 3.1 |
ROA on average assets derived (%) | — | 4.6 | 2.4 | 2.4 |
Borrowings to equity derived (%) | 39.3 | 23.3 | 19.6 | 16.4 |
Total liabilities to equity derived (%) | 53.4 | 37.2 | 30.9 | 26.8 |
Asset turnover derived (x) | — | 0.20 | 0.19 | — |
Interest coverage OI to interest expense (x) | — | — | — | 8.5 |
Geographic Revenue
| Indicator | Figure | Source |
|---|---|---|
Share of FY2020 investment gains from overseas | More than 30% | CEO statement, Dealsite, 2 Feb 2021 |
US portfolio companies listed on Nasdaq (cumulative) | 19 | Asiae CORE, 27 Aug 2026 |
Solasta portfolio as of Jan 2021 | 29 companies invested, 15 Nasdaq-listed | Dealsite, 26 Jan 2021 |
Boston-sourced exits: Arcellx, Kymera, Atea | KRW 32.3 bn invested → KRW 324.1 bn recovered (derived sum) | Asiae CORE, 27 Aug 2026 |
Planned annual US deployment (2019 plan) | KRW 30–50 bn per year, up from KRW 20–30 bn | Dealsite, 2 Jul 2019 |
Japan exposure | First LP commitment to Japanese VC funds in 2025 | Asiae CORE, 27 Aug 2026 |
Share Price and Market Valuation
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Year-end share price (KRW) | 2,215 | 2,750 | 2,430 | 2,885 |
Year-end market cap (KRW Bn) | 267.6 | 332.3 | 293.9 | 349.5 |
Year-end P/B (x) | — | 1.29 | 1.13 | 1.31 |
Year-end P/E derived (x) | 132 | 20.0 | 35.4 | 42.1 |
Share Price & Returns
| Period | Return |
|---|---|
Year-to-date (vs end-2025 KRW 2,885) | −2.9% |
vs end-2024 (KRW 2,430) | +15.2% |
vs end-2023 (KRW 2,750) | +1.8% |
vs IPO price (KRW 1,500, Nov 2018) | +86.7% |
vs 24 Apr 2026 peak close (KRW 18,720) | −85.0% |
Valuation Multiples
| Multiple | Aju IB | Basis |
|---|---|---|
P/E (TTM to Jun-2026) | ~8.2x | NI TTM KRW 41.49 bn (derived) |
P/E (FY2025) | ~40.8x | NI KRW 8.31 bn (derived) |
P/B (2Q 2026 equity) | ~1.13x | Equity KRW 299.3 bn (derived) |
P/B (FY2025 equity) | ~1.27x | Equity KRW 266.9 bn (derived) |
Peer reference | VC peer median P/B ~0.91x | AlphaDistill, 19 Aug 2026 (independent publication, not a broker) |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2018 | FY2019 | FY2025 |
|---|---|---|---|
Dividend per share (KRW) | 25 | 35 | 70 |
Total dividend (KRW Bn) | 3.0 | 4.1 | — |
Analyst Conclusions
Management guidance
There is no quantitative earnings guidance. Management's stated near-term agenda is to:
-
Complete the KRW 200 bn Super-Gap Scale-up 2.0 fund and the KRW 50 bn Frontier-Tech fund.
-
Harvest more than ten portfolio IPOs in 2H 2026.
-
Continue recurring exits and new investment to reward shareholders and LPs (Asiae, 14 Aug 2026).
Consensus growth expectations
None available (no coverage).
Bull case
-
Normalised fee base is stepping up. AUM rose about 23% from end-2024 to 2Q 2026. New PE and policy funds should lift annual management fees above the ~KRW 18 bn FY2023–FY2024 level, raising the floor under earnings. TTM fee income was already KRW 34.8 bn.
-
Hidden value at a low multiple. At ~1.1x book and ~8x TTM earnings, the market appears to assign little value to a SpaceX stake, residual AI positions (Lambda, Databricks, Cohere) and a full-cycle franchise with a documented ~10x US exit record.
-
Cyclical tailwinds. Korean venture investment recovered to KRW 13.6 trn in 2025, with KRW 14.3 trn of fund formation. Together with the National Growth Fund and pension reforms, this favours large incumbents, and Aju IB already holds a GP slot.
Bear case
-
1H 2026 was a one-off. A large part of the record profit came from SpaceX fair-value gains and the Arcellx take-out. SpaceX fell ~50% from its peak within weeks of listing, so 2H 2026 marks could reverse part of the gain. Without these, core profitability has run at only KRW 8–12 bn of NI.
-
Alignment and governance. The CEO sold ~94% of his shares and the parent sold 7% near the peak. With owner-family board seats, this weakens the minority-shareholder case and may keep a discount on the stock.
-
Disclosure opacity and theme dependence. The undisclosed SpaceX cost and stake, plus zero sell-side coverage, mean the stock trades on themes rather than on fundamentals. The 8x rise and 85% fall within six months illustrate the resulting volatility.
Key catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | What to watch |
|---|---|---|
| 3Q 2026 results | Mid-November 2026 | Direction of SpaceX mark; performance fees; whether TTM ROE stays near 14% |
| Low-P/B company list | From November 2026 | Whether Aju IB is listed; any value-up response (buybacks, dividend policy) |
| SpaceX lock-up expiry and realisation | Late 2026 (timing not disclosed) | Any disclosure of realised proceeds or distributions |
| Super-Gap Scale-up 2.0 close | 2H 2026 | Final size vs KRW 200 bn target; Teachers' Pension matching |
| Frontier-Tech fund close | 2026–27 | KRW 50 bn target |
| 2H 2026 IPOs | Rolling | Dabeeo, PGT, MBD, NexI listings and post-IPO performance |
| E-Bridge integration | 2026–27 | Earnings growth; partnership announcements |
| FY2026 dividend | Feb–Mar 2027 | Whether payout rises with record earnings |
| Parent shareholding | Ongoing | Any further sell-downs from 53.37% |
Analyst verdict
Aju IB Investment is a credible, long-established Korean VC/PE manager. Its listed equity has been repriced twice in 2026. It first traded as a SpaceX proxy and then as a firm whose controlling shareholder and CEO sold into that rally.
The underlying business has improved materially. AUM reached KRW 2.55 trn in 2Q 2026. The PE franchise now carries a KRW 316 bn fund and a ~KRW 250 bn platform buyout. The US platform has produced roughly KRW 324 bn of realisations from just KRW 32 bn invested in three biotechs. The balance sheet carries net cash. 1H 2026 delivered OI of KRW 46.2 bn, more than four times FY2025's full-year figure.
The record result should nonetheless be treated as partly non-recurring. Through FY2025, the firm earned 3–7% returns on equity. Its fee base of roughly KRW 18–20 bn barely exceeded fixed costs of roughly KRW 16 bn in SG&A. Profit above breakeven depended on realisations that are inherently lumpy. The SpaceX gain is unrealised, its size is undisclosed, and the market value of the underlying stock has been volatile since listing.
At about KRW 2,800 per share (~1.1x book, ~8x TTM earnings), the valuation no longer reflects the April euphoria and is close to book. That is reasonable for a business whose sustainable ROE probably sits in the mid-to-high single digits, with upside if fee-bearing AUM keeps growing and the 2H 2026 IPO pipeline converts.
The stock is likely to remain a high-volatility, theme-driven instrument until two things change. First, management would need to disclose more about its largest positions. Second, the owner family would need to align more visibly with minority holders, through clearer capital-return policy or reduced selling. Investors should anchor on book value and recurring fees rather than on SpaceX headlines. The near-term tests are the 3Q 2026 mark-to-market and the close of the Super-Gap Scale-up 2.0 fund.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Background | Tenure / notes | Source |
|---|---|---|---|---|
Kim Ji-won (김지원) | CEO and inside director | Born 1967; Yonsei University (business administration); joined 1999 (then KIBO Capital) | CEO since Mar 2015; re-appointed Mar 2025 for 2 years (term to Mar 2027) | Dealsite, 6 Feb 2025 & 27 Mar 2025 |
Moon Kyu-young (문규영) | Non-standing director | Chairman, Aju Group | Re-appointed Mar 2024 | Dealsite, 28 Mar 2024 |
Lee Hwang-cheol (이황철) | Non-standing director | CEO of (주)아주 since 2023; formerly Mercer Consulting (2006), Aju HR head (2013), Aju chief of staff (2015) | Appointed Mar 2024 | Dealsite, 28 Mar 2024 |
Moon Yoon-hoe (문윤회) | Non-standing director | Born 1981; eldest son of Chairman Moon; CEO of Aju hotel division since 2009; CEO of (주)아주 Vision Community since 2023 | Appointed Mar 2025 (2-year term); replaced resigned PE inside director Choi Yong-jin | Dealsite, 27 Mar 2025 |
Hwang Kyu-min (황규민) | Non-standing director | Lawyer, Hankyul Law Firm | Re-appointed Mar 2025 | Dealsite, 27 Mar 2025 & 28 Mar 2024 |
Yoon Seok-jin (윤석진) | Outside director | Former president of KIST; reported as a designer of the Lee Jae-myung administration's science and technology policy | Serving as of Jun 2025 | Dealsite, 5 Jun 2025 |
Han Chang-soo (한창수) | Outside director (audit committee) | Professor of psychiatry, Korea University College of Medicine; clinical-research and health-policy advisory background | Re-appointed Mar 2024 | Dealsite, 28 Mar 2024 |
Third outside director | Outside director | — | — | — |
Executive Leadership Team
| Name | Title | Background | Source |
|---|---|---|---|
Park Gye-hoon (박계훈) | Head of VC Investment Division and AC Division | — | Asiae CORE, 27 Aug 2026 |
Park Se-geun (박세근) | Managing Director, Global Investment Division; lead manager of Super-Gap Scale-up 2.0 | Samsung SDI, NC, IMM Investment; portfolio includes Lezhin Entertainment, Delicious, PNP | Dealsite, 22 Jul 2026 |
Jung Dae-seok (정대석) | Division head (본부장) | Sold 19,650 shares (~KRW 353 m) in Apr 2026 | Dealsite, 21 Aug 2026 |
Yoon Chang-soo (윤창수) | Head, Venture Investment 1 (2021 appointment) | Joined 1999; sourced DTNC, Carver Korea, Actro | Dealsite, 7 Jan 2021 |
Heo Byung-du (허병두) | Head of Risk Management and compliance officer (2021) | CPA, formerly Samil PwC | Dealsite, 7 Jan 2021 |
Kim Tae-seung (김태승) | Head of PE Investment (2021) | Mirae Asset Daewoo, Deloitte Anjin; sourced Point Mobile | Dealsite, 7 Jan 2021 |
Derek (Dong-min) Yoon | Head, Solasta Ventures (Boston) | MSF, Boston College; MBA, Babson; RBS healthcare banking; Berwind Private Equity | Asiae CORE, 27 Aug 2026 |
Michael Jeon | Partner and head, Solasta Nexus | BS EECS, UC Berkeley; MS software engineering, Carnegie Mellon; MBA, MIT Sloan; ex-Samsung | Asiae CORE, 27 Aug 2026; Dealsite, 2 Jul 2019 |
Major Shareholders
| Holder | Stake | Notes | Source |
|---|---|---|---|
(주)아주 (Aju Corporation) | 53.37% | After block sale of 8,481,780 shares at KRW 18,700 (Apr 2026); previously 60.54% | AlphaDistill, 19 Aug 2026 |
CEO Kim Ji-won | ~0.01% (12,416 shares) | Sold 187,584 of ~200,000 shares in Apr 2026 | AI-Fortunate blog, Apr 2026; MarketScreener |
Retail shareholders | ~40,000 holders (Mar 2025) | — | Dealsite, 27 Mar 2025 |
Competitive Landscape
Key Competitors
| Competitor | Listing | Overlap with Aju IB | Relative positioning |
|---|---|---|---|
Mirae Asset Venture Investment | KOSDAQ 100790 | Large generalist VC; SpaceX holder; US/Asia platform | #1 listed VC by market cap (above KRW 2 trn, Jun 2026); direct SpaceX-theme peer |
Korea Investment Partners | Unlisted (Korea Investment Holdings) | Largest domestic VC; global offices | Larger AUM; affiliated with a securities group |
Atinum Investment | KOSDAQ 021080 | Large generalist VC | #1 listed VC by FY2024 fees (KRW 46.9 bn); strong 2025 |
DSC Investment | KOSDAQ 241520 | Early/growth VC; FuriosaAI | Deep-tech theme peer; buyback and cancellation in 2026 |
LB Investment | KOSDAQ 309960 | Generalist VC; owner-family board | Comparable governance profile; strong 2025 realisations |
Woori Technology Investment | KOSDAQ 041190 | VC with Dunamu stake | #3 listed VC by market cap (KRW 459.5 bn, Jun 2026) |
STIC Investments | KOSPI 026890 | PE and growth | Competitor for PE LP capital |
SBI Investment Korea | KOSDAQ 019550 | VC | Smaller |
TS Investment | KOSDAQ 246690 | Growth, secondary, M&A; owns accelerator New Paradigm | Full-cycle model peer |
IMM Investment | Unlisted | Large VC/PE; secondaries | Competitor for policy and pension mandates |
Premier Partners | Unlisted | Biotech-strong VC/PE | Biotech competitor |
Company K Partners, Stonebridge Ventures, Lindeman Asia, Nau IB Capital | KOSDAQ 307930 / 330730 / 277070 / 293580 | Mid-sized VCs | Smaller-scale peers |
Peer Comparison FY2024
| Metric | Aju IB | Mirae Asset Venture | Atinum Investment | DSC Investment |
|---|---|---|---|---|
9M 2025 operating revenue (KRW Bn) | — | 126.0 | 54.7 | 24.6 |
9M 2025 operating income (KRW Bn) | 6.2 (derived) | 12.9 | 31.4 | 6.1 |
9M 2025 OI growth YoY (%) | -43 (derived vs 10.8) | -39 | 227 | -34 |
FY2024 management + performance fees (KRW Bn) | 23.1 (fee income) | — | 46.9 | 26.9 |
AUM (KRW trn) | 2.55 (2Q 2026) | — | ~1.2 (2023 reference) | — |



